Bifunctional cytochrome P450/NADPH--P450 reductase

BE0001563ProteinBacillus megateriumcyp102A1

Functions as a fatty acid monooxygenase (PubMed:11695892, PubMed:14653735, PubMed:16403573, PubMed:16566047, PubMed:17077084, PubMed:1727637, PubMed:17868686, PubMed:18004886, PubMed:18298086, PubMed:18619466, PubMed:18721129, PubMed:19492389, PubMed:20180779, PubMed:21110374, PubMed:21875028, PubMed:3106359, PubMed:7578081). It is acted on by 3 drugs in DrugBank.

Gene name
cyp102A1
UniProtKB entry
P14779Swiss-Prot
Cellular location
Cytoplasm
Residues / weight
1,049 residues · 117,780 Da
Also known as
cyp102 · Cytochrome P450(BM-3) · Cytochrome P450BM-3 · Fatty acid monooxygenase · Flavocytochrome P450 BM3

Resolves to

Protein
UniProtP14779UniProt nameCPXB_PRIM2
Gene
GenBank142798
Structure
PDB1BU7PDB1BVYPDB1FAG
Drugs

What you can answer from here — as of September 04, 2024

3DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
7GO termsFunction, process and component, as structured annotations
Sign in
4Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
10+ReferencesStructured and connected to the statements they support
Sign in

Which compounds in development act on Bifunctional cytochrome P450/NADPH--P450 reductase, and which indications are they being tested in?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In